Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NYSE
Website: perrigo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2025 | Buy → Hold | Argus | |
| 1/6/2025 | $34.00 → $27.00 | Overweight → Neutral | Piper Sandler |
| 9/24/2024 | $50.00 → $30.00 | Hold | Jefferies |
| 11/17/2023 | $37.00 | Overweight | Piper Sandler |
| 3/7/2023 | $49.00 | Buy | Canaccord Genuity |
| 9/14/2022 | $46.00 | Hold → Buy | Argus |
| 9/6/2022 | $48.00 → $54.00 | Equal Weight → Overweight | Wells Fargo |
| 11/11/2021 | $59.00 → $55.00 | Outperform | Raymond James |
| 10/14/2021 | $59.00 | Market Perform → Outperform | Raymond James |
| 9/30/2021 | $45.00 → $63.00 | Hold → Buy | Jefferies |
Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested
DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit
DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o
DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key
Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN, Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic gr
DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS 2025 Global Consumer and Retail Conference, on Wednesday, March 12 at 10 AM ET in New York City. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (O
DUBLIN, Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 25, 2025, to shareholders of record on March 7, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Produ
--WNBA and Opill® continue partnership with Level The Court initiative-- GRAND RAPIDS, Mich., Feb. 4, 2025 /PRNewswire/ -- Today, Opill®— the first and only daily birth control pill available without a prescription in the U.S. —launched an educational college campus tour and the next phase of its multiyear partnership with the Women's National Basketball Association (WNBA) with a goal of expanding reproductive health education and access to birth control resources. Experience the full interactive Multichannel News Release here: https://www.multivu.com/perrigo/9316851-en-opill-extends-mission-of-breaking-down-birth-control-barriers Opill® and the WNBA, in partnership with the Black Women's H
DUBLIN, Ireland, Jan. 31, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2024 financial results after the U.S. equity markets close on February 27, 2025. The Company plans to host its Virtual Investor Day on February 28, 2025, beginning at 8:00 AM EST. Interested parties are invited to access the Virtual Investor Day event at Perrigo-Investor-Day-2025.open-exchange.net/welcome and are encouraged to register in advance. About Perrigo Perrigo Comp
Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s
4 - PERRIGO Co plc (0001585364) (Issuer)
3 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4/A - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor
SC 13G - PERRIGO Co plc (0001585364) (Subject)
SC 13G - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G/A - PERRIGO Co plc (0001585364) (Subject)
SC 13G - PERRIGO Co plc (0001585364) (Subject)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4/A - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested
DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit
DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o
DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key
Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN, Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic gr
DUBLIN, Feb. 19, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved a 5% increase in the Company's quarterly dividend to $0.290 per share, or $1.16 per share on an annual basis, up from $0.276 per share. This marks the 22nd consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 25, 2025, to shareholders of record on March 7, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Produ
DUBLIN, Ireland, Jan. 31, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2024 financial results after the U.S. equity markets close on February 27, 2025. The Company plans to host its Virtual Investor Day on February 28, 2025, beginning at 8:00 AM EST. Interested parties are invited to access the Virtual Investor Day event at Perrigo-Investor-Day-2025.open-exchange.net/welcome and are encouraged to register in advance. About Perrigo Perrigo Comp
Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially Reaffirms Fiscal 2024 Adjusted EPS Outlook DUBLIN, Nov. 6, 2024 /PRNewswire/ -- Third Quarter 2024 Highlights: Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decrea
DUBLIN, Nov. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-manage
DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial results on Wednesday, November 6, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 96443. A taped replay
Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s
Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat
DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts.
Dutch Bros Inc. (NYSE:BROS, "Dutch Bros"))), a west coast-based drive-thru beverage company focused on making a massive difference one cup at a time, has announced the appointment of Todd Penegor to its Board of Directors, where he will serve as an independent director. Penegor brings extensive executive leadership experience from his tenure as President and CEO of The Wendy's Company (NASDAQ:WEN), along with previous roles at Kellanova (formerly Kellogg Company) (NYSE:K) and Ford Motor Company (NYSE:F). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624176723/en/Todd Penegor (Photo: Business Wire) "Todd is a values-based lea
Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN, May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this year. Roberto Khoury, a consumer self-care veteran with more than 20 years of experience cultivating successful branded consumer products and pan-European brands, will be appointed to lead Perrigo's CSCI segment. To ensure business c
Appoints Experienced Consumer Packaged Goods Executive Catherine "Triona" Schmelter as EVP and President, Consumer Self-Care Americas (CSCA) and Global Portfolio Optimization DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of Catherine "Triona" Schmelter as Executive Vice President and President, Consumer Self-Care Americas (CSCA) and Global Portfolio Optimization. In this role, Ms. Schmelter will lead the strategic direction, growth, and profitability of the CSCA business in addition to overseeing the global portfolio evolution process to consistently deliver Perrigo's long-term growt
DUBLIN, June 8, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of industry professional Patrick Lockwood-Taylor as its new President, Chief Executive Officer and member of the Board of Directors, effective June 30, 2023. Mr. Lockwood-Taylor joins Perrigo from Bayer AG, where he served a dual role as President of the approximately $15 billion revenue Bayer U.S. business and Regional President of Consumer Health North America, achieving high single-digit growth during his tenure. As Regiona
DUBLIN, May 9, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that Murray S. Kessler has notified the Company of his intent to retire as President and Chief Executive Officer, with a target effective date of July 31, 2023. Mr. Kessler will be working with the Board of Directors to secure his successor and to ensure a smooth transition. Murray S. Kessler said, "After 18 years as a public company CEO, I have decided that this is the right time for me to retire. I joined Perrigo almost 5 years ago to lead t
S-8 - PERRIGO Co plc (0001585364) (Filer)
10-Q - PERRIGO Co plc (0001585364) (Filer)
8-K - PERRIGO Co plc (0001585364) (Filer)
8-K - PERRIGO Co plc (0001585364) (Filer)
DEFA14A - PERRIGO Co plc (0001585364) (Filer)
DEF 14A - PERRIGO Co plc (0001585364) (Filer)
PRE 14A - PERRIGO Co plc (0001585364) (Filer)
144 - PERRIGO Co plc (0001585364) (Subject)
10-K - PERRIGO Co plc (0001585364) (Filer)
8-K - PERRIGO Co plc (0001585364) (Filer)
Argus downgraded Perrigo from Buy to Hold
Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously
Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously
Piper Sandler initiated coverage of Perrigo with a rating of Overweight and set a new price target of $37.00
Canaccord Genuity initiated coverage of Perrigo with a rating of Buy and set a new price target of $49.00
Argus upgraded Perrigo from Hold to Buy and set a new price target of $46.00
Wells Fargo upgraded Perrigo from Equal Weight to Overweight and set a new price target of $54.00 from $48.00 previously
Raymond James reiterated coverage of Perrigo with a rating of Outperform and set a new price target of $55.00 from $59.00 previously
Raymond James upgraded Perrigo from Market Perform to Outperform and set a new price target of $59.00
Jefferies upgraded Perrigo from Hold to Buy and set a new price target of $63.00 from $45.00 previously